Ginkgo Bioworks Holdings Inc vs Opendoor Technologies Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.32 (market cap $505.73M), while Opendoor Technologies Inc trades at $3.48 (market cap $3.45B). The key difference: Opendoor Technologies Inc is far larger — about 6.8× Ginkgo Bioworks Holdings Inc's market cap. Which is the better fit depends on your goals.
| DNA | OPEN | |
|---|---|---|
Market Cap | $505.73M | $3.45B |
Sector | Health | Real Estate |
52-Week High | $16.14 | $10.52 |
52-Week Low | $5.48 | $2.42 |
Enterprise Value | $607.68M | $4.52B |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Opendoor Technologies (OPEN) trades at $3.48, down 0.29% today, reflecting ongoing challenges in the housing market. The stock shows bearish technical signals with mixed earnings performance - beating Q4 2025 estimates but missing Q1 and Q2 2026 expectations. Revenue has declined from $15.6B in 2022 to $4.4B in 2025, with net losses widening to $1.3B last year. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $3.58 offers modest upside potential.
The outlook remains challenging as high interest rates and housing market weakness pressure Opendoor's iBuying model. While the company maintains strong cash flow from operations ($1.05B in 2025) and trades below book value, persistent losses and competitive threats from Zillow create significant headwinds. Investors should weigh the company's market position against ongoing profitability concerns in a difficult real estate environment.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →